In ₹ Crore except Per Share Latest Annual	NOVARTIND FY25	BPLPHARMA FY23	JENBURPH FY26	KPL FY24	Peer Average
Valuation — at last close
P/E	—	45.39×	—	—	45.39×
P/B	—	5.78×	—	—	5.78×
EV/EBITDA	—	51.68×	—	—	51.68×
Market Cap	—	₹1,105 Cr	—	—	₹1,105 Cr
Growth
Revenue CAGR 3Y	-2.24%	—	◆ 7.26%	—	7.26% -131%
Revenue CAGR 5Y	-6.20%	—	◆ 9.07%	—	9.07% -168%
Net Income CAGR 3Y	◆ 69.01%	—	12.18%	—	12.18% +467%
Profitability
EBITDA Margin	◆ 25.66%	9.80%	23.81%	21.69%	18.43% +39%
Net Income Margin	◆ 28.32%	11.16%	20.59%	—	15.88% +78%
Return on Common Equity	13.19%	13.63%	◆ 18.84%	—	16.23% -19%
Return on Capital Employed	11.34%	—	—	◆ 19.78%	19.78% -43%
Return on Assets	10.78%	9.25%	◆ 16.45%	—	12.85% -16%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.04×	—	0.43×	0.23× -100%
Interest Coverage	◆ 115.88×	7.10×	—	4.54×	5.82× +1891%
Scale — latest FY
Revenue / Total Income	₹356 Cr	₹218 Cr	₹169 Cr	₹307 Cr	₹231 Cr +54%
Net Income	₹101 Cr	₹24.3 Cr	₹34.7 Cr	—	₹29.5 Cr +242%
Total Assets	₹948 Cr	₹308 Cr	₹226 Cr	₹398 Cr	₹311 Cr +205%
EPS	—	₹42.14	—	—	₹42.14
Book Value per Share	—	₹330.83	—	—	₹330.83

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.